CRDF Q4 2025 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CRDFCardiff Oncology, Inc.

$139M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$243,000+60.9% YoY

Gross Profit

$20,0008.2% margin

Operating Income

-$8M-3221.0% margin

Net Income

-$7M-2970.0% margin

EPS (Diluted)

$-0.11

QoQ Revenue Growth

+102.5%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$62M

Total Liabilities

$16M

Stockholders' Equity

$45M

Cash & Equivalents

$17M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$243,000	$151,000	+60.9%
Gross Profit	$20,000	$151,000	-86.8%
Operating Income	-$8M	-$13M	+37.7%
Net Income	-$7M	-$12M	+38.8%